Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.40 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.40 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.38 |
| ▸ | HTR6 | P50406 | 1/20 | 0.38 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.38 |
| ▸ | LCK | P06239 | 2/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.37 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | MAT2A | P31153 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22899524 | 0.88 | LCK (0.46) | IGF1RIRAK4LCK | |
| SCHEMBL18359590 | 0.87 | IRAK4 (0.47) | IRAK4 | |
| SCHEMBL24766244 | 0.86 | LCK (0.48) | IGF1RIRAK4LCK | |
| SCHEMBL24766699 | 0.81 | TTK (0.48) | IGF1RIRAK4PIM1LCKMKNK1 | |
| SCHEMBL18359546 | 0.81 | IRAK4 (0.63) | IRAK4LCK | |
| SCHEMBL24765705 | 0.80 | TTK (0.47) | IGF1RIRAK4PIM1CYP1A2 | |
| SCHEMBL25783428 | 0.80 | TTK (0.47) | IGF1RIRAK4PIM1CYP1A2 | |
| SCHEMBL22149188 | 0.80 | IGF1R (0.38) | IGF1RIRAK4TGFBR1LCKCYP1A2 | |
| SCHEMBL30227664 | 0.75 | IRAK4 (0.35) | IGF1RMAPK1IRAK4 | |
| SCHEMBL30007851 | 0.75 | KDM4E (0.42) | LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230212174-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVE AND USE THEREOF | TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212174-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVE AND USE THEREOF | TENCENT TECHNOLOGY (SHENZHEN) COMPANY LIMITED (CN) | 2023-07-06 | — | — | US | disclosed |
| WO-2022257732-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVES AND APPLICATION THEREOF | 腾讯科技（深圳）有限公司 | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212174-A1 | PYRROLO[2,1-F][1,2,4]TRIAZINE DERIVATIVE AND USE THEREOF | CYP11B2, CYP11B1, CYP4F11 | IGF1R 4527/4885MAPK1 857/4885PDE10A 1755/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.